{"id":75516,"date":"2025-12-02T07:44:13","date_gmt":"2025-12-02T07:44:13","guid":{"rendered":"https:\/\/newonclusivstg.wpengine.com\/?p=75516"},"modified":"2026-02-12T16:45:29","modified_gmt":"2026-02-12T16:45:29","slug":"top-pharma-companies-on-linkedin","status":"publish","type":"post","link":"https:\/\/onclusive.com\/en-gb\/resources\/blog\/top-pharma-companies-on-linkedin\/","title":{"rendered":"The LinkedIn Pharma Power Rankings: Who&#8217;s Winning the Conversation in 2025?"},"content":{"rendered":"\n<section\n    class=\"block-pcon\">\n\n      \n\t\t\t<div class=\"post_content--wrapper\">\n\t\t\t\t<div class=\"post_content--copy  \">\n\t\t\t\t\t<div class=\"post_content--copy-inner-wrapper\">\n\n\n\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"post_content-copy-wrapper\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t  \t\t<p><span style=\"font-weight: 400;\">Leading pharmaceutical companies are discovering how to align their innovation story with what patients and professionals really want to hear<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">When pharma companies on LinkedIn share their stories , they rightfully lead with innovation. When LinkedIn users discuss these same companies, they want to understand access and affordability alongside those breakthroughs.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">This isn&#8217;t a crisis-it&#8217;s an opportunity. Our analysis of 228,100 LinkedIn mentions across top pharmaceutical companies reveals a strategic opening: the industry has built tremendous credibility around innovation, and now has the chance to extend that narrative to address the questions their audience is actively asking. This study was conducted by combining <a href=\"https:\/\/onclusive.com\/en-gb\/products\/media-monitoring\/\" target=\"_blank\" rel=\"noopener\">mainstream media monitoring<\/a> and s<a href=\"https:\/\/onclusive.com\/en-gb\/products\/social-listening\/\" target=\"_blank\" rel=\"noopener\">ocial media listening insights<\/a> using <b>Onclusive 360 <\/b>\u200b\u200band <b>Onclusive Social.<\/b><\/span><\/p>\n<p>In an industry where scientific advancement moves at unprecedented speed, the companies that can tell the complete story-from lab to patient-will build lasting competitive advantage.<\/p>\n<p>&nbsp;<\/p>\n<h2><strong>Table of Content<\/strong><\/h2>\n<p><a href=\"#key\">Key Takeaways about Pharmaceutical Company on LinkedIn<\/a><br \/>\n<a href=\"#owned\">The Strong Foundation: What Pharma Companies on LinkedIn Are Doing Right<\/a><br \/>\n<a href=\"#earned\">The Audience Insight: What Stakeholders Are Curious About<\/a><br \/>\n<a href=\"#opprtunity\">The 22-Point Opportunity: Strategic Alignment<\/a><br \/>\n<a href=\"#recommandations\">Strategic Recommendations: Amplifying What&#8217;s Working<\/a><br \/>\n<a href=\"#conclusion\">The Path Forward: Building on Strong Foundations<\/a><br \/>\n<a href=\"#conclusion\">Conclusion<\/a><\/p>\n<p><a href=\"#FAQ\">Frequently Asked Questions about Pharmaceutical Company on LinkedIn<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n \n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\t\t\n<\/section> \n\n\n\n\n\n<section\n  id=\"key\"  class=\"block-pcon\">\n\n      \n\t\t\t<div class=\"post_content--wrapper\">\n\t\t\t\t<div class=\"post_content--copy  \">\n\t\t\t\t\t<div class=\"post_content--copy-inner-wrapper\">\n\n\n\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"post_content-copy-wrapper\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t  \t\t<h2><b>Key Takeaways about Pharma Companies on LinkedIn\u00a0<\/b><\/h2>\n<ul>\n<li><b>AstraZeneca leads pharmaceutical owned media activity on LinkedIn <\/b><span style=\"font-weight: 400;\">with 223 posts in three months, followed by Boehringer Ingelheim (180) and Pfizer (126) <b>during the period studied. <\/b><\/span><\/li>\n<li><b>50.30% of pharma content focuses on Innovation &amp; R&amp;D<\/b><span style=\"font-weight: 400;\"> \u2013 demonstrating the industry&#8217;s commitment to showcasing scientific advancement<\/span><\/li>\n<li><b>28.3% of audience conversations center on Drug Pricing &amp; Access<\/b><span style=\"font-weight: 400;\"> \u2013 revealing a significant gap between the content provided by pharmaceutical companies and the audience&#8217;s interest in the first topic discussed. <\/span><\/li>\n<li><b>26.3% of discussions involve Clinical Trials &amp; Research<\/b><span style=\"font-weight: 400;\"> \u2013 showing high audience engagement with scientific content<\/span><\/li>\n<li><b>18.4% of conversations focus on vaccines<\/b><span style=\"font-weight: 400;\"> \u2013 indicating sustained public interest in preventive medicine<\/span><\/li>\n<li><b>The opportunity<\/b><span style=\"font-weight: 400;\">: Pharmaceutical companies can extend their strong innovation narrative by proactively addressing access and affordability topics<\/span><\/li>\n<li><span style=\"font-weight: 400;\">\u00a0<\/span><b>The solution<\/b><span style=\"font-weight: 400;\">: A balanced content mix that maintains innovation leadership while answering the questions audiences are actively asking<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n \n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\t\t\n<\/section> \n\n\n\n\n\n<section\n  id=\"owned\"  class=\"block-pcon\">\n\n      \n\t\t\t<div class=\"post_content--wrapper\">\n\t\t\t\t<div class=\"post_content--copy  \">\n\t\t\t\t\t<div class=\"post_content--copy-inner-wrapper\">\n\n\n\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"post_content-copy-wrapper\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t  \t\t<h2><b>The Strong Foundation: What Pharma Companies Are Doing Right<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Over the last three months, pharmaceutical companies demonstrated good LinkedIn engagement, thanks to their regular and relevant publication, with <\/span><b>AstraZeneca leading at 223 posts<\/b><span style=\"font-weight: 400;\">, followed by Boehringer Ingelheim (180), Pfizer (126), and Bristol-Myers Squibb (122). This consistent, high-quality output shows the industry&#8217;s commitment to professional engagement *. This is one of the findings of our brand new <a href=\"https:\/\/onclusive.com\/en-gb\/resources\/whitepaper\/pharmaceutical-industry-scan-2025\/\" target=\"_blank\" rel=\"noopener\">Industry Scan Media and Social Media report<\/a> covering the pharmaceutical industry.\u00a0<\/span><\/p>\n<h3><a href=\"https:\/\/onclusive.com\/en-gb\/resources\/whitepaper\/pharmaceutical-industry-scan-2025\/\" target=\"_blank\" rel=\"noopener\"><img fetchpriority=\"high\" decoding=\"async\" fetchpriority=\"high\" class=\"aligncenter wp-image-75598 size-full\" src=\"https:\/\/onclusive.com\/wp-content\/uploads\/2025\/12\/EN-top-pharma-linkedin-Owned-media-publication-by-companies-.png\" alt=\"Owned Media: pharma Companies on Linkedin-What Communicate this drug companies? \" width=\"800\" height=\"480\" srcset=\"https:\/\/onclusive.com\/wp-content\/uploads\/2025\/12\/EN-top-pharma-linkedin-Owned-media-publication-by-companies-.png 800w, https:\/\/onclusive.com\/wp-content\/uploads\/2025\/12\/EN-top-pharma-linkedin-Owned-media-publication-by-companies--300x180.png 300w, https:\/\/onclusive.com\/wp-content\/uploads\/2025\/12\/EN-top-pharma-linkedin-Owned-media-publication-by-companies--768x461.png 768w, https:\/\/onclusive.com\/wp-content\/uploads\/2025\/12\/EN-top-pharma-linkedin-Owned-media-publication-by-companies--640x384.png 640w\" sizes=\"(max-width: 639px) 98vw, (max-width: 1199px) 64vw, 770px\" \/><\/a><\/h3>\n<p><em><span style=\"font-weight: 400;\">Owned Media: What Companies Communicate. Publication by companies. Scope: main LinkedIn accounts of companies. Based on an analysis of 1752 mentions during 3 months.\u00a0<\/span><\/em><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<h3><b>Innovation Leadership: A Strategic Necessity<\/b><\/h3>\n<p><b>50.30% of pharmaceutical companies&#8217; LinkedIn content focuses on Innovation &amp; R&amp;D-<\/b><span style=\"font-weight: 400;\">and for excellent reasons.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">This heavy investment in innovation storytelling makes strategic sense:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Investor confidence<\/b><span style=\"font-weight: 400;\">: Demonstrating pipeline strength and future revenue potential<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Price justification<\/b><span style=\"font-weight: 400;\">: Connecting high R&amp;D costs to breakthrough therapies<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Talent attraction<\/b><span style=\"font-weight: 400;\">: Positioning companies as leaders in cutting-edge science<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Competitive differentiation<\/b><span style=\"font-weight: 400;\">: Showcasing unique capabilities and therapeutic advances<\/span><\/li>\n<\/ul>\n<p><b>This isn&#8217;t misguide, it&#8217;s mission-critical.<\/b><span style=\"font-weight: 400;\"> Without innovation, pharmaceutical companies can&#8217;t serve patients. The 50% allocation reflects the industry&#8217;s core purpose: advancing medical science.<\/span><\/p>\n<p>&nbsp;<\/p>\n<h3><b>Patient-Centric Progress<\/b><\/h3>\n<p><b>Diseases &amp; Therapies content (26%)<\/b><span style=\"font-weight: 400;\"> shows the industry&#8217;s evolution toward patient-focused storytelling. Companies are increasingly:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Humanizing their brands through patient impact stories<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Raising awareness of underserved disease areas<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Creating emotional connections beyond products<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Demonstrating concrete health outcomes<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">This shift from &#8220;what we make&#8221; to &#8220;who we help&#8221; represents meaningful progress in corporate communication.<\/span><\/p>\n<h3><b>Smart Employer Branding<\/b><\/h3>\n<p><b>Employment &amp; Careers (3.70%)<\/b><span style=\"font-weight: 400;\"> reflects sophisticated multi-purpose communication. Pharmaceutical companies recognize LinkedIn as both a stakeholder engagement platform and a talent acquisition channel.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">In a fierce competition for data scientists, AI specialists, and biotech researchers, these companies are smartly leveraging their innovation narrative for recruitment. <\/span><b>This is strategic efficiency, not mission drift.<\/b><\/p>\n<p><em>(* Study conducted over a period of 3 months. The number of posts per company may vary depending on their news and seasonality.)<\/em><\/p>\n<p>&nbsp;<\/p>\n<p><a href=\"https:\/\/onclusive.com\/en-gb\/resources\/whitepaper\/pharmaceutical-industry-scan-2025\/\" target=\"_blank\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter wp-image-75614 size-full\" src=\"https:\/\/onclusive.com\/wp-content\/uploads\/2025\/12\/ENG-pharma-report-CTA.png\" alt=\"Download our complete Pharmaceutical Industry Scan 2025 for share of voice rankings, sentiment analysis, and competitive benchmarking across all major platforms. \" width=\"800\" height=\"300\" srcset=\"https:\/\/onclusive.com\/wp-content\/uploads\/2025\/12\/ENG-pharma-report-CTA.png 800w, https:\/\/onclusive.com\/wp-content\/uploads\/2025\/12\/ENG-pharma-report-CTA-300x113.png 300w, https:\/\/onclusive.com\/wp-content\/uploads\/2025\/12\/ENG-pharma-report-CTA-768x288.png 768w, https:\/\/onclusive.com\/wp-content\/uploads\/2025\/12\/ENG-pharma-report-CTA-640x240.png 640w\" sizes=\"(max-width: 639px) 98vw, (max-width: 1199px) 64vw, 770px\" \/><\/a><\/p>\n<p><b>Want to see how your pharmaceutical company performs on LinkedIn compared to competitors?<\/b><span style=\"font-weight: 400;\"> Download our complete Pharmaceutical Industry Scan 2025 for share of voice rankings, disruptive topics, media presence and competitive benchmarking across all major platforms. <\/span><b>[<a href=\"https:\/\/onclusive.com\/en-gb\/resources\/whitepaper\/pharmaceutical-industry-scan-2025\/\" target=\"_blank\" rel=\"noopener\">Download the Full Report<\/a>]\u00a0<\/b><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n \n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\t\t\n<\/section> \n\n\n\n\n\n<section\n  id=\"earned\"  class=\"block-pcon\">\n\n      \n\t\t\t<div class=\"post_content--wrapper\">\n\t\t\t\t<div class=\"post_content--copy  \">\n\t\t\t\t\t<div class=\"post_content--copy-inner-wrapper\">\n\n\n\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"post_content-copy-wrapper\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t  \t\t<h2><b>The Audience Insight: What Stakeholders Are Curious About<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Now for the fascinating part: what happens when pharmaceutical companies on LinkedIn <\/span><i><span style=\"font-weight: 400;\">aren&#8217;t<\/span><\/i><span style=\"font-weight: 400;\"> controlling the narrative reveals incredible audience engagement opportunities.<\/span><\/p>\n<p>&nbsp;<\/p>\n<h3><b>The Access Conversation: An Invitation for Leadership<\/b><\/h3>\n<p><b>28.3% of earned media conversations about pharma companies focus on Drug Pricing &amp; Access.<\/b><\/p>\n<p><span style=\"font-weight: 400;\">Here&#8217;s the positive reframe: <\/span><b>nearly a third of your audience is actively engaged with healthcare access topics and waiting for pharmaceutical companies to lead this conversation.<\/b><\/p>\n<p><span style=\"font-weight: 400;\">This represents enormous opportunity:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Audience engagement<\/b><span style=\"font-weight: 400;\">: People care deeply about these issues and want to understand them<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Thought leadership space<\/b><span style=\"font-weight: 400;\">: Relatively few companies are addressing this proactively<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Trust-building potential<\/b><span style=\"font-weight: 400;\">: Transparent communication here creates differentiation<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Policy influence<\/b><span style=\"font-weight: 400;\">: Educated stakeholders become advocates<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<table>\n<tbody>\n<tr>\n<td><b>\ud83d\udcb0Drug Pricing &amp; Access<\/b><\/td>\n<td><b>28.3%<\/b><\/td>\n<\/tr>\n<tr>\n<td><b>\ud83d\udd2cClinical Trials &amp; Research<\/b><\/td>\n<td><b>26.3%<\/b><\/td>\n<\/tr>\n<tr>\n<td><b>\ud83d\udc89Vaccine Discussion<\/b><\/td>\n<td><b>18.4%<\/b><\/td>\n<\/tr>\n<tr>\n<td><b>\ud83d\udcbcCareer &amp; Jobs<\/b><\/td>\n<td><b>8.6%<\/b><\/td>\n<\/tr>\n<tr>\n<td><b>\u26a0\ufe0fSide Effects &amp; Safety<\/b><\/td>\n<td><b>6.5%<\/b><\/td>\n<\/tr>\n<tr>\n<td><b>\u274cIndustry Criticism<\/b><\/td>\n<td><b>4.3%<\/b><\/td>\n<\/tr>\n<tr>\n<td><b>\ud83d\udcddOther<\/b><\/td>\n<td><b>2.5%<\/b><\/td>\n<\/tr>\n<tr>\n<td><b>\u2764\ufe0fPatient Experiences<\/b><\/td>\n<td><b>1.6%<\/b><\/td>\n<\/tr>\n<tr>\n<td><b>\ud83c\udf1fInnovation Praise<\/b><\/td>\n<td><b>1.1%<\/b><\/td>\n<\/tr>\n<tr>\n<td><b>\ud83d\udccaCorporate News<\/b><\/td>\n<td><b>1.0%<\/b><\/td>\n<\/tr>\n<tr>\n<td><b>\ud83c\udfe5Healthcare System<\/b><\/td>\n<td><b>0.9%<\/b><\/td>\n<\/tr>\n<tr>\n<td><b>\u2696\ufe0fRegulatory &amp; Legal<\/b><\/td>\n<td><b>0.3%<\/b><\/td>\n<\/tr>\n<tr>\n<td><b>\ud83e\ude7aDisease Awareness<\/b><\/td>\n<td><b>0.2%<\/b><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><em>The most popular topic categories on LinkedIn\u00a0 in conversation related to pharmaceutical companies<\/em><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">The conversations happening include:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Questions about pricing structures (curiosity, not just criticism)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Interest in patient assistance programs<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Comparisons that reveal complexity of different healthcare systems<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Calls for industry innovation in access models<\/span><\/li>\n<\/ul>\n<p><b>The key insight<\/b><span style=\"font-weight: 400;\">: People aren&#8217;t rejecting pharmaceutical innovation, they want to understand how that innovation becomes accessible. This is an invitation to complete your story, not abandon it.<\/span><\/p>\n<p>&nbsp;<\/p>\n<h3><b>Clinical Trials: High Engagement Opportunity<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">At <\/span><b>26.3%<\/b><span style=\"font-weight: 400;\">, Clinical Trials &amp; Research ranks remarkably high in earned media, nearly matching company-controlled R&amp;D messaging.<\/span><\/p>\n<p><b>This is phenomenal news.<\/b><span style=\"font-weight: 400;\"> It means:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Growing health literacy<\/b><span style=\"font-weight: 400;\">: Audiences want to understand the science<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Active participation interest<\/b><span style=\"font-weight: 400;\">: Patients seeking trial opportunities<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Transparency appetite<\/b><span style=\"font-weight: 400;\">: Stakeholders engaging with methodology and results<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Partnership mindset<\/b><span style=\"font-weight: 400;\">: Communities wanting to contribute to medical advances<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">The distinction in conversation types reveals opportunity:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Company messaging<\/b><span style=\"font-weight: 400;\">: Pipeline strength, breakthrough potential, scientific leadership<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>User discussions<\/b><span style=\"font-weight: 400;\">: Practical participation, eligibility questions, real-world outcomes<\/span><\/li>\n<\/ul>\n<p><b>Smart pharmaceutical companies can bridge this easily<\/b><span style=\"font-weight: 400;\"> by making trial information more accessible while maintaining scientific rigor.<\/span><\/p>\n<h3><b>Vaccines: Sustained Interest Creating Dialogue Opportunities<\/b><\/h3>\n<p><b>18.4% of conversations focus on vaccines, <\/b><span style=\"font-weight: 400;\">demonstrating sustained public interest in preventive medicine.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">While sentiment is mixed, this creates valuable opportunities:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Education platform<\/b><span style=\"font-weight: 400;\">: High engagement means people want to learn<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Scientific communication<\/b><span style=\"font-weight: 400;\">: Chance to explain complex immunology accessibly<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Public health leadership<\/b><span style=\"font-weight: 400;\">: Industry expertise in critical health issues<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Long-term relationship building<\/b><span style=\"font-weight: 400;\">: Ongoing dialogue rather than one-time transactions<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">The diversity of perspectives (pro-vaccine advocacy, safety questions, scientific analysis) indicates <\/span><b>an active, engaged audience willing to discuss complex topics-<\/b><span style=\"font-weight: 400;\">exactly what pharmaceutical companies need for meaningful stakeholder relationships.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n \n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\t\t\n<\/section> \n\n\n\n\n\n<section\n  id=\"opportunity\"  class=\"block-pcon\">\n\n      \n\t\t\t<div class=\"post_content--wrapper\">\n\t\t\t\t<div class=\"post_content--copy  \">\n\t\t\t\t\t<div class=\"post_content--copy-inner-wrapper\">\n\n\n\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"post_content-copy-wrapper\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t  \t\t<h2><b>The 22-Point Opportunity: Strategic Alignment<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Here&#8217;s the strategic opportunity:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Pharma companies on LinkedIn dedicate <\/span><b>50.30%<\/b><span style=\"font-weight: 400;\"> of ccontent to Innovation &amp; R&amp;D<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">LinkedIn users dedicate <\/span><b>28.3%<\/b><span style=\"font-weight: 400;\"> of their pharma discussions to Drug Pricing &amp; Access<\/span><\/li>\n<\/ul>\n<p><b>This 22-percentage-point gap represents untapped communication territory<\/b><span style=\"font-weight: 400;\"> where pharmaceutical companies can differentiate themselves, build trust, and complete their innovation narrative.<\/span><\/p>\n<p>&nbsp;<\/p>\n<h3><b>Why This Opportunity Is Valuable<\/b><\/h3>\n<ol>\n<li><b> First-Mover Advantage<\/b><\/li>\n<\/ol>\n<p><span style=\"font-weight: 400;\">Few pharmaceutical companies are proactively addressing access and affordability with the same sophistication they bring to innovation messaging. Early movers will establish thought leadership.<\/span><\/p>\n<ol start=\"2\">\n<li><b> Complete Brand Story<\/b><\/li>\n<\/ol>\n<p><span style=\"font-weight: 400;\">Innovation without access is incomplete. Companies that connect breakthrough science to patient access tell a more compelling, credible story.<\/span><\/p>\n<ol start=\"3\">\n<li><b> Talent Attraction Enhancement<\/b><\/li>\n<\/ol>\n<p><span style=\"font-weight: 400;\">Top professionals, especially younger generations, want to work for companies that demonstrate both scientific excellence and societal impact. Addressing access strengthens employer brand.<\/span><\/p>\n<ol start=\"4\">\n<li><b> Stakeholder Trust Building<\/b><\/li>\n<\/ol>\n<p><span style=\"font-weight: 400;\">Transparent communication about complex issues like pricing builds credibility that pays dividends during both routine operations and crisis situations.<\/span><\/p>\n \n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\t\t\n<\/section> \n\n\n\n\n\n<section\n  id=\"recommendations\"  class=\"block-pcon\">\n\n      \n\t\t\t<div class=\"post_content--wrapper\">\n\t\t\t\t<div class=\"post_content--copy  \">\n\t\t\t\t\t<div class=\"post_content--copy-inner-wrapper\">\n\n\n\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"post_content-copy-wrapper\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t  \t\t<h2><b>Strategic Recommendations: Amplifying What&#8217;s Working<\/b><\/h2>\n<h3><b>1. Extend Your Innovation Story<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">You&#8217;ve built incredible credibility around R&amp;D. Now complete the narrative by connecting innovation to access:<\/span><\/p>\n<p><b>Evolution approach<\/b><span style=\"font-weight: 400;\">: &#8220;We&#8217;re developing breakthrough cancer therapies, and here&#8217;s how we&#8217;re ensuring patients can benefit from them&#8221;<\/span><\/p>\n<p><span style=\"font-weight: 400;\">This doesn&#8217;t replace innovation messaging; it enhances it by answering the natural follow-up question your audience is already asking.<\/span><\/p>\n<h3><b>2. Lead the Access Conversation<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">Rather than avoiding pricing discussions, lead them proactively:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Explain R&amp;D costs transparently (you&#8217;re already sharing the science)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Showcase patient assistance programs prominently<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Share success stories of patients who accessed medications<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Discuss industry challenges candidly<\/span><\/li>\n<\/ul>\n<p><b>This demonstrates confidence and builds trust.<\/b><\/p>\n<h3><b>3. Make Trial Content More Accessible<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">You&#8217;re already investing in clinical trials communication. Enhance it by adding:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Clear, patient-friendly eligibility criteria<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Participation process explanations<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Patient testimonials from actual trial participants<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Transparent results sharing (successes and learnings)<\/span><\/li>\n<\/ul>\n<p><b>This leverages your existing strength while addressing audience interest.<\/b><\/p>\n<h3><b>4. Optimize Content Mix<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">Consider adjusting your content allocation:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>40%<\/b><span style=\"font-weight: 400;\"> Innovation &amp; R&amp;D (maintain strength)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>25%<\/b><span style=\"font-weight: 400;\"> Diseases &amp; Therapies (continue patient focus)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>20%<\/b><span style=\"font-weight: 400;\"> Access &amp; Affordability (address audience interest)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>10%<\/b><span style=\"font-weight: 400;\"> Clinical Trials (make practical)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>5%<\/b><span style=\"font-weight: 400;\"> Other topics<\/span><\/li>\n<\/ul>\n<p><b>This maintains your innovation leadership while addressing the full patient journey.<\/b><\/p>\n<h3><b>5. Activate Your Greatest Asset: People<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">Your scientists, clinicians, and patient advocates have tremendous credibility:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Encourage researchers to explain their work in accessible terms<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Have patient services teams showcase assistance programs<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Let employees share why they&#8217;re passionate about both science and access<\/span><\/li>\n<\/ul>\n<p><b>This humanizes complex topics and builds authentic connections.<\/b><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n \n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\t\t\n<\/section> \n\n\n\n\n\n<section\n  id=\"conclusion\"  class=\"block-pcon\">\n\n      \n\t\t\t<div class=\"post_content--wrapper\">\n\t\t\t\t<div class=\"post_content--pullout_copy  \">\n\t\t\t\t\t<div class=\"post_content--pullout_copy-inner-wrapper\">\n\n\n\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"post_content-copy-wrapper\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<blockquote class=\"pullout_copy\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t  \t\t<h2><b>The Path Forward: Building on Strong Foundations<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Pharmaceutical companies have built remarkable LinkedIn presence around innovation, and rightfully so. This foundation of scientific credibility is invaluable.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The opportunity now is to extend this strength by addressing the questions your engaged audience is actively asking. They&#8217;re not rejecting your innovation story; they want to understand the complete journey from breakthrough to bedside.<\/span><\/p>\n<p><b>50.30% innovation. 28.3% pricing interest. 22 points of opportunity.<\/b><\/p>\n<p><span style=\"font-weight: 400;\">The companies that will lead aren&#8217;t those that abandon their innovation narrative. They&#8217;re the ones that complete it by connecting scientific advancement to patient access, making innovation and affordability complementary rather than competing narratives.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">This is the next evolution of pharmaceutical leadership: <\/span><b>companies confident enough to discuss complexity, transparent enough to acknowledge challenges, and sophisticated enough to tell the complete story of how breakthrough science becomes accessible healthcare.<\/b><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<h2><b>Conclusion<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Your LinkedIn audience is engaged, curious, and asking questions. They&#8217;re interested in clinical trials, want to understand pricing, and care about access. This isn&#8217;t opposition-it&#8217;s an invitation to deeper dialogue.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The pharmaceutical companies that accept this invitation, bringing the same sophistication to access discussions that they bring to innovation storytelling, will build the stakeholder trust that defines industry leadership.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><i><span style=\"font-weight: 400;\"><strong>About the data:<\/strong> This analysis covers 228,100 LinkedIn mentions across the 30 leading pharmaceutical companies, plus 1,752 owned media posts from corporate accounts, covering a three-month period. Among the companies analysed are Pfizer, AstraZeneca, Novo Nordisk, Merck &amp; Co., Sanofi, Johnson &amp; Johnson, Novartis, GSK, Amgen and Roche.<br \/>\nProduced with specialized Onclusive tools:<br \/>\n<a href=\"https:\/\/onclusive.com\/en-gb\/products\/media-monitoring\/\" target=\"_blank\" rel=\"noopener\">Media Monitoring and Analysis<\/a>:<span style=\"color: #000000;\"> Onclusive 360, <a href=\"https:\/\/onclusive.com\/en-gb\/products\/social-listening\/\" target=\"_blank\" rel=\"noopener\">Social Media Monitoring Insights<\/a> and Analysis: <a style=\"color: #000000;\" href=\"https:\/\/onclusive.com\/products\/social-listening\/\" target=\"_blank\" rel=\"noopener\">Onclusive Social\u00a0<\/a><\/span><br \/>\n<\/span><\/i><\/p>\n \n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/blockquote>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\t\t\n<\/section> \n\n\n\n\n\n<section\n  id=\"FAQ\"  class=\"block-pcon\">\n\n      \n\t\t\t<div class=\"post_content--wrapper\">\n\t\t\t\t<div class=\"post_content--copy  \">\n\t\t\t\t\t<div class=\"post_content--copy-inner-wrapper\">\n\n\n\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"post_content-copy-wrapper\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t  \t\t<h2><a href=\"https:\/\/onclusive.com\/en-gb\/resources\/whitepaper\/pharmaceutical-industry-scan-2025\/\" target=\"_blank\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter wp-image-75629\" src=\"https:\/\/onclusive.com\/wp-content\/uploads\/2025\/12\/social-cards-1.png\" alt=\"Pharmaceutical Industry Scan 2025: Download the full report!\" width=\"840\" height=\"474\" srcset=\"https:\/\/onclusive.com\/wp-content\/uploads\/2025\/12\/social-cards-1.png 1240w, https:\/\/onclusive.com\/wp-content\/uploads\/2025\/12\/social-cards-1-300x169.png 300w, https:\/\/onclusive.com\/wp-content\/uploads\/2025\/12\/social-cards-1-1024x578.png 1024w, https:\/\/onclusive.com\/wp-content\/uploads\/2025\/12\/social-cards-1-768x434.png 768w, https:\/\/onclusive.com\/wp-content\/uploads\/2025\/12\/social-cards-1-640x361.png 640w, https:\/\/onclusive.com\/wp-content\/uploads\/2025\/12\/social-cards-1-1200x677.png 1200w\" sizes=\"(max-width: 639px) 98vw, (max-width: 1199px) 64vw, 770px\" \/><\/a><\/h2>\n<p><span style=\"font-weight: 400;\">Ready to dive deeper? Our comprehensive report includes detailed analysis of pharma companies market share of voice, social media trends, consumer insights, and upcoming trend that will shape the pharma industry. <\/span><a href=\"https:\/\/onclusive.com\/en-gb\/resources\/whitepaper\/pharmaceutical-industry-scan-2025\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">Access the complete report now\u00a0<\/span><\/a><\/p>\n<h2><\/h2>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<h2><b>Frequently Asked Qu<\/b><b>estions about Pharmaceutical Companies on LinkedIn\u00a0<\/b><\/h2>\n<p>&nbsp;<\/p>\n<h3><b>Which pharmaceutical company posts the most on LinkedIn?<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">AstraZeneca leads with 223 LinkedIn posts over a three-month period, followed by Boehringer Ingelheim (180 posts) and Pfizer (126 posts). These companies demonstrate consistent engagement with their professional audiences.<\/span><\/p>\n<h3><b>What do pharmaceutical companies talk about on LinkedIn?<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">Innovation &amp; R&amp;D dominates at 50.30% of content, followed by Diseases &amp; Therapies (26%), Employment &amp; Careers (3.70%), and other topics including cancer &amp; oncology, vaccines, and CSR initiatives.<\/span><\/p>\n<h3><b>What topics get the most engagement on pharma LinkedIn posts?<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">According to our analysis of 228,100 mentions, Drug Pricing &amp; Access generates 28.3% of conversations, Clinical Trials &amp; Research accounts for 26.3%, and Vaccine Discussion drives 18.4% of engagement.<\/span><\/p>\n<h3><b>Why is there a gap between what pharma companies post and what audiences discuss?<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">Pharmaceutical companies focus heavily on innovation (50.30%) to demonstrate scientific leadership and pipeline strength, while audiences are equally interested in practical access questions (28.3%). This 22-point gap represents an opportunity for companies to extend their narrative.<\/span><\/p>\n<h3><b>How can pharmaceutical companies improve their LinkedIn strategy?<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">Companies can maintain their innovation strength while adding more content about access, affordability, and patient assistance programs. A balanced approach, connecting breakthrough science to patient acces, creates a more complete and compelling narrative.<\/span><\/p>\n<h3><b>Do pharmaceutical companies use LinkedIn for recruiting?<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">Yes. Employment &amp; Careers content (3.70%) reflects LinkedIn&#8217;s dual purpose as both a stakeholder communication platform and talent acquisition channel. Companies compete fiercely for data scientists, researchers, and AI specialists.<\/span><\/p>\n<h3><b>What&#8217;s the sentiment around pharma companies on LinkedIn?<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">Sentiment is mixed. Innovation and clinical trial content tends to be positive, while pricing discussions generate more critical engagement. Vaccine content shows the most polarized sentiment with strong opinions on both sides.<\/span><\/p>\n<h3><b>How many LinkedIn users discuss pharmaceutical companies?<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">Our analysis tracked 228,100 LinkedIn mentions across the top 10 pharmaceutical companies over three months, indicating substantial professional and public engagement with pharma topics.<\/span><\/p>\n<h3><b>What&#8217;s the best content mix for pharmaceutical companies on LinkedIn?<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">We recommend: 40% Innovation &amp; R&amp;D, 25% Diseases &amp; Therapies, 20% Access &amp; Affordability, 10% Clinical Trials, and 5% other topics. This maintains innovation leadership while addressing audience interests.<\/span><\/p>\n<h3><b>Which pharmaceutical companies should I follow on LinkedIn?<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">For innovation content: AstraZeneca, Pfizer, Boehringer Ingelheim. For patient-focused content: Johnson &amp; Johnson, GSK. For comprehensive industry perspective: follow multiple companies to see different communication approaches.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n \n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\t\t\n<\/section> \n\n\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":31,"featured_media":75552,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","inline_featured_image":false,"footnotes":""},"audience":[],"topic":[],"region":[],"class_list":["post-75516","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/onclusive.com\/en-gb\/wp-json\/wp\/v2\/posts\/75516","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/onclusive.com\/en-gb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/onclusive.com\/en-gb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/onclusive.com\/en-gb\/wp-json\/wp\/v2\/users\/31"}],"replies":[{"embeddable":true,"href":"https:\/\/onclusive.com\/en-gb\/wp-json\/wp\/v2\/comments?post=75516"}],"version-history":[{"count":0,"href":"https:\/\/onclusive.com\/en-gb\/wp-json\/wp\/v2\/posts\/75516\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/onclusive.com\/en-gb\/wp-json\/wp\/v2\/media\/75552"}],"wp:attachment":[{"href":"https:\/\/onclusive.com\/en-gb\/wp-json\/wp\/v2\/media?parent=75516"}],"wp:term":[{"taxonomy":"audience","embeddable":true,"href":"https:\/\/onclusive.com\/en-gb\/wp-json\/wp\/v2\/audience?post=75516"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/onclusive.com\/en-gb\/wp-json\/wp\/v2\/topic?post=75516"},{"taxonomy":"region","embeddable":true,"href":"https:\/\/onclusive.com\/en-gb\/wp-json\/wp\/v2\/region?post=75516"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}